Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2039384 | 0.81 | FPR2 (0.32) | — | |
| SCHEMBL3635531 | 0.77 | — | — | |
| SCHEMBL26777143 | 0.76 | NOS1 (0.39) | NOS1SMN1; SMN2NPC1GAARAB9A | |
| SCHEMBL26766002 | 0.74 | NOS1 (0.38) | NOS1SMN1; SMN2NPC1GAARAB9A | |
| SCHEMBL26777147 | 0.74 | NOS1 (0.38) | NOS1SMN1; SMN2NPC1GAARAB9A | |
| SCHEMBL16790691 | 0.70 | NOS1 (0.38) | NOS1SMN1; SMN2LMNAPKM | |
| SCHEMBL19597507 | 0.70 | NOS1 (0.38) | NOS1SMN1; SMN2LMNAPKM | |
| SCHEMBL25929689 | 0.70 | NOS1 (0.38) | NOS1SMN1; SMN2LMNAPKM | |
| SCHEMBL12133606 | 0.69 | ALOX5 (0.34) | NOS1NPC1RAB9A | |
| SCHEMBL21238429 | 0.69 | NOS1 (0.36) | NOS1SMN1; SMN2NPC1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691810-B2 | Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20110281842-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281842-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | NOS1 2915/4885SMN1; SMN2 4417/4885NPC1 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.